GNI Group Ltd
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical tri… Read more
Market Cap & Net Worth: GNI Group Ltd (3G6)
GNI Group Ltd (F:3G6) has a market capitalization of $987.26 Million (€961.80 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #8365 globally and #903 in its home market, demonstrating a -2.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GNI Group Ltd's stock price €17.30 by its total outstanding shares 55595190 (55.60 Million).
GNI Group Ltd Market Cap History: 2015 to 2026
GNI Group Ltd's market capitalization history from 2015 to 2026. Data shows growth from $268.97 Million to $987.26 Million (13.27% CAGR).
GNI Group Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GNI Group Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
GNI Group Ltd's market cap is 0.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.10x
GNI Group Ltd's market cap is 1.10 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $268.97 Million | $1.02 Billion | -$623.00 Million | 0.26x | N/A |
| 2016 | $327.56 Million | $1.31 Billion | -$513.10 Million | 0.25x | N/A |
| 2017 | $798.94 Million | $2.65 Billion | -$175.21 Million | 0.30x | N/A |
| 2018 | $449.88 Million | $5.02 Billion | -$200.13 Million | 0.09x | N/A |
| 2019 | $1.22 Billion | $7.45 Billion | $181.84 Million | 0.16x | 6.72x |
| 2020 | $798.94 Million | $9.77 Billion | $1.26 Billion | 0.08x | 0.64x |
| 2021 | $633.44 Million | $12.69 Billion | $1.07 Billion | 0.05x | 0.59x |
| 2022 | $544.99 Million | $17.42 Billion | $388.82 Million | 0.03x | 1.40x |
| 2023 | $1.00 Billion | $26.01 Billion | $8.09 Billion | 0.04x | 0.12x |
| 2024 | $1.21 Billion | $23.61 Billion | $1.10 Billion | 0.05x | 1.10x |
Competitor Companies of 3G6 by Market Capitalization
Companies near GNI Group Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to GNI Group Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
GNI Group Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, GNI Group Ltd's market cap moved from $268.97 Million to $ 987.26 Million, with a yearly change of 13.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €987.26 Million | +35.16% |
| 2025 | €730.46 Million | -39.62% |
| 2024 | €1.21 Billion | +20.45% |
| 2023 | €1.00 Billion | +84.29% |
| 2022 | €544.99 Million | -13.96% |
| 2021 | €633.44 Million | -20.71% |
| 2020 | €798.94 Million | -34.58% |
| 2019 | €1.22 Billion | +171.46% |
| 2018 | €449.88 Million | -43.69% |
| 2017 | €798.94 Million | +143.90% |
| 2016 | €327.56 Million | +21.78% |
| 2015 | €268.97 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GNI Group Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $987.26 Million USD |
| MoneyControl | $987.26 Million USD |
| MarketWatch | $987.26 Million USD |
| marketcap.company | $987.26 Million USD |
| Reuters | $987.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.